Fun with Funds: Exploring the XBI
Welcome back to Fun with Funds, where we break down intriguing financial vehicles in plain English. Today’s guest is
SPACs: Biotech’s Shortcut to the Big Time, or Just a Shortcut to Disaster?
SPACs and Biotech: A Cautionary Tale
In recent years, Special Purpose Acquisition Companies (SPACs) emerged as a popular alternative to
The Davos Effect: Is It About the Debate, the Clout, or Just the View?
Davos in January. The snow-dusted mountains, the high-altitude air of importance, and the collective hum of thousands of people all
The Problem with Timid Founders: Breaking Free from the Research Mindset
It is a truth universally acknowledged that a brilliant researcher in possession of a good idea is often too timid
A Case Study on IP-Backed Finance: Lessons from South Korea
A few years ago, if someone had told me you could walk into a bank, lay a patent on the
Welcome to Medicocristan: Why Mediocrity Is the Enemy of Breakthroughs
Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion
Consulting: The Final Refuge of the Corporate Castaway
It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides
The Problem with (Most) MBAs: When the Masters of the Universe Miss the Point
The MBA, that once-illustrious badge of business acumen, has long held a peculiar sway over boardrooms and balance sheets. It
Tail Risks in Drug Development: Case Studies and Lessons Learned
Drug development requires vast investments of capital and time. Even after extensive research and clinical testing, unforeseen safety problems or
Breaking the Mold: Harnessing Non-Conformity for Innovation and Advantage
Conformity is often the lubricant of social interaction. It smooths edges, creates predictability, and allows societies and organizations to function
